Share on:
RS&RS Scientific Ltd - Innovation contest
Inhalable Precision Gene Therapy for Lung Cancer

InhaleGene – Inhalable Precision Gene Therapy for Lung Cancer is a pioneering treatment designed to tackle small cell lung cancer (SCLC) — a fast-progressing and drug-resistant cancer with few effective options.

Unlike conventional systemic therapies, which flood the entire body and cause severe side effects, InhaleGene delivers treatment directly to the lungs through inhalation. This approach ensures that the therapeutic agents reach the tumor site in high local concentrations, where they are needed most, while dramatically reducing exposure to other organs such as the liver, kidneys, and heart.

The benefits of inhalation therapy are transformative:



  1. Precise lung targeting: The inhaled nanoparticles accumulate in the lungs, creating a local drug “depot” that maintains steady and prolonged therapeutic levels within lung tissue.




  2. Lower systemic toxicity: Because most of the therapy remains localized, patients experience fewer side effects compared to IV-administered drugs or viral gene delivery systems.




  3. Higher dosing potential: The localized delivery allows for higher effective doses without reaching toxic levels in the bloodstream.




  4. Non-invasive and home-based: Patients can self-administer the therapy using a portable inhaler, eliminating hospital stays and improving quality of life.




  5. Enhanced immune response: By acting directly within the tumor microenvironment, inhalation delivery helps transform resistant “cold” tumors into inflamed, immune-active ones, making existing therapies more effective.

How the people voted
  • 0% -
Comment:
4000 characters remaining.